Scarica l'app Stockscreener
5.7873
8.99%
0.4773
Precedente Chiudi:
$5.31
Aprire:
$5.12
Volume 24 ore:
4,247
Relative Volume:
0.38
Capitalizzazione di mercato:
$58.10M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
-1.07%
1M Prestazione:
+7.37%
6M Prestazione:
-15.77%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$5.12
$5.80
Intervallo di 1 settimana:
$5.12
$6.61
Portata 52W:
$3.81
$10.28
Serina Therapeutics Inc Stock (SER) Company Profile
Nome
Serina Therapeutics Inc
Settore
Industria
Telefono
(256) 327-9630
Indirizzo
601 GENOME WAY, HUNTSVILLE
Confronta SER con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SER
Serina Therapeutics Inc
|
5.7873 | 58.10M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
501.15 | 126.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
605.61 | 65.06B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
649.67 | 37.54B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
259.39 | 32.56B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
255.77 | 26.40B | 3.81B | -644.79M | -669.77M | -6.24 |
Serina Therapeutics Inc Borsa (SER) Ultime notizie
Serina Therapeutics to Present at JonesResearch Virtual CNS Day - The Manila Times
Serina Therapeutics CEO to Showcase Revolutionary CNS Drug Technology: Key Presentation Details Revealed - Stock Titan
Serina Therapeutics Says May Offer And Sell Shares Of Common Stock Of Up To $13.3 Million - marketscreener.com
Serina Therapeutics Receives Second $5 Million Tranche to Strengthen Cash Position Ahead of Phase 1 Clinical Trial in Advanced Parkinson's Disease Patients - The Globe and Mail
Serina Therapeutics to Present at the 4th LNP Formulation & Process Development Summit - GlobeNewswire
Revolutionary Drug Delivery Tech Could Make mRNA Vaccines Safer: New Trial Data - Stock Titan
Serina Therapeutics closes $5 million funding for Parkinson’s trial By Investing.com - Investing.com Canada
Serina Therapeutics Secures $5 Million Funding - MarketScreener
Serina Therapeutics closes $5 million funding for Parkinson’s trial - Investing.com
Serina Therapeutics Secures $5 Million in Funding to - GlobeNewswire
Revolutionary Parkinson's Treatment Gets $5M Boost: Serina's New Drug Heads to Clinical Trials - Stock Titan
Serina Therapeutics to Present at the Jones Healthcare and Technology Innovation Conference - GlobeNewswire
Serina's Game-Changing POZ Platform Takes Center Stage at Major Healthcare Conference - Stock Titan
Serina Therapeutics Files For Mixed Shelf Of Upto $100 MillionSEC Filing - MarketScreener
Serina Therapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights - GlobeNewswire
Serina Therapeutics to Present Novel Data on Non-Immunogenic Lipid Nanoparticles at ACS Spring 2025 Meeting - Nasdaq
Serina Therapeutics to Present at the American Chemistry Society (ACS) Spring 2025 Meeting - GlobeNewswire
Serina Cuts $11.2M Debt, Secures $10M Investment While Revenue Drops 98% - Stock Titan
Jones Trading Initiates Coverage of Serina Therapeutics (SER) with Buy Recommendation - Nasdaq
Serina Therapeutics initiated with a Buy at JonesResearch - TipRanks
Serina Therapeutics Appoints Dr. Venkatesan to Board - TipRanks
Serina Therapeutics Appoints Dr. Jay Venkatesan to Board of Directors - Nasdaq
Serina Therapeutics Appoints Dr. Jay Venkatesan to its Board of Directors - GlobeNewswire
Former Alpine Immune Sciences Founder Who Led $4.9B Exit Takes Board Seat at Serina - StockTitan
Huntsville biotech firm partnering with Pfizer lands $10 million for Parkinson’s trial - MSN
Serina secures additional $5 million for Parkinson's trial - MSN
Serina secures additional $5 million for Parkinson's trial By Investing.com - Investing.com Australia
Stocks to Watch: Palantir Technologies, Synaptics, J&J Snack Foods, Serina Therapeutics - MarketWatch
Serina Therapeutics's Shares Up Following $5M of Equity Financing - MarketWatch
Serina Therapeutics Receives Second $5 Mln Tranche To Strengthen Cash Position - Marketscreener.com
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Serina Therapeutics receives funding to advance SER-252 into clinical trial - TipRanks
Serina Therapeutics Secures $5 Million for SER-252 Trials - TipRanks
Serina Therapeutics Receives Second $5 Million Tranche to - GlobeNewswire
Parkinson's Breakthrough: Serina Therapeutics Lands Premium-Priced $5M Investment to Advance Novel Treatment - StockTitan
Serina Therapeutics Secures Additional $5 Million Financing to Advance SER-252 into Phase 1 Trial for Advanced Parkinson's Disease - Nasdaq
Stocks to Watch: Serina Therapeutics, Powell Max, Silexion Therapeutics - MarketWatch
Serina Therapeutics Shares Rise After Sale of UniverXome Subsidiary - MarketWatch
Serina Therapeutics Sells UniverXome Subsidiary - MarketWatch
Serina Therapeutics Announces Sale of UniverXome Subsidiary - GlobeNewswire
Serina Therapeutics Achieves Debt-Free Status After $11.2M UniverXome Sale, Sharpens Focus on Parkinson's Drug - StockTitan
Serina Therapeutics Welcomes Karen J. Wilson to its Board of Directors - GlobeNewswire
Serina Therapeutics, Inc. Appoints Karen J. Wilson to its Board of Directors -January 14, 2025 at 05:25 pm EST - Marketscreener.com
Serina Therapeutics director Bailey Gregory buys shares worth $17,744 By Investing.com - Investing.com Australia
Serina Therapeutics director Bailey Gregory buys shares worth $17,744 - Investing.com
Serina Therapeutics expands equity incentive plan By Investing.com - Investing.com Australia
Serina Therapeutics expands equity incentive plan - Investing.com India
Serina Therapeutics to Present at Tribe Public’s Webinar Event "Enabling Continuous Drug Delivery for Parkinson's Disease & Beyond" on Wednesday, December 18, 2024 - The Globe and Mail
Serina Therapeutics to Present at Tribe Public’s Webinar - GlobeNewswire
Serina Therapeutics to Unveil Breakthrough Parkinson's Treatment Strategy in Upcoming Webinar - StockTitan
Serina Therapeutics to Present at the 3rd Annual LNP Immunogenicity & Toxicity Summit - GlobeNewswire
Serina Therapeutics Inc Azioni (SER) Dati Finanziari
Non sono disponibili dati finanziari per Serina Therapeutics Inc (SER). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
Serina Therapeutics Inc Azioni (SER) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Bailey Gregory | Director |
Dec 17 '24 |
Buy |
4.59 |
3,866 |
17,745 |
67,243 |
| Bailey Gregory | Director |
Sep 20 '24 |
Buy |
6.03 |
1,137 |
6,851 |
63,377 |
| Bailey Gregory | Director |
Sep 19 '24 |
Buy |
6.11 |
11,679 |
71,384 |
62,240 |
| Bailey Gregory | Director |
Sep 18 '24 |
Buy |
6.23 |
2,709 |
16,873 |
50,561 |
| MINTZ STEVEN | Director |
Sep 12 '24 |
Buy |
6.47 |
6,000 |
38,814 |
17,443 |
| Bailey Gregory | Director |
Aug 20 '24 |
Buy |
8.25 |
1,776 |
14,652 |
47,582 |
| Bailey Gregory | Director |
Aug 19 '24 |
Buy |
7.93 |
6,400 |
50,760 |
45,806 |
| Bailey Gregory | Director |
Aug 16 '24 |
Buy |
7.31 |
6,400 |
46,780 |
39,406 |
| Bailey Gregory | Director |
Aug 15 '24 |
Buy |
6.65 |
6,400 |
42,577 |
33,006 |
| MINTZ STEVEN | Director |
Aug 15 '24 |
Buy |
6.59 |
7,593 |
50,033 |
11,443 |
0.47%
2.63%
Capitalizzazione:
|
Volume (24 ore):